Month: September 2022
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). BMF-219 displayed single agent potency, surpassing greater than 90% inhibition at clinically relevant exposures in both DLBCL and MM cell lines and patient-derived samples. A Trial…
Read More
– 141 MDS Patients Enrolled –– Topline Data Anticipated 1H:2023 – Excerpt from the Press Release: SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS).…
Read More
Preclinical data showed synergistic and additive effects of combination imetelstat and ruxolitinib Study intended to explore potential for disease modification with imetelstat in earlier, frontline myelofibrosis setting Single-agent imetelstat currently being studied in a separate Phase 3 trial designed to confirm clinically meaningful benefits observed in relapsed/refractory MF patients in Phase 2 study Excerpt from…
Read More
Excerpt from the Press Release: BERWYN, Pa., Aug. 24, 2022 /PRNewswire/ — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson’s Disease (PD) has been dosed. The Phase 3 trial…
Read More
Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) Excerpt from the Press Release: BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer…
Read More
mRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron Variant Pending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in September Clinical Data Available for Moderna’s Bivalent COVID-19 Booster Vaccines Have Met All Primary Endpoints and Support Request for Emergency Use Authorization Excerpt from the Press Release: CAMBRIDGE, MA / ACCESSWIRE / August 23, 2022 / Moderna, Inc.…
Read More
Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal) DERBY: 36% monthly, p<0.0001; 29% every-other-month (EOM), p=0.0002 OAKS: 24% monthly, p=0.0080; 25% EOM, p=0.0007 Consistent with expectations, no clinically meaningful difference on key functional endpoints observed at 24 months Continued to demonstrate…
Read More
Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure Excerpt from the Press Release: MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced the launch…
Read More
Independent Data Presented at the World Federation of Interventional and Therapeutic Neuroradiology 2022 Annual Meeting Highlights the Benefits of Vessel-Matching with Zoom Reperfusion Catheters Excerpt from the Press Release: CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that new data evaluating the utility of the Zoom Stroke Solution were presented at the World Federation of Interventional…
Read More- « Previous
- 1
- …
- 4
- 5
- 6